Compare ResMed Inc. (RMD) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tempus AI — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Tempus AI trades at $71.1 (market cap $12.58B). The key difference: ResMed Inc. is far larger — about 2.5× Tempus AI's market cap, and ResMed Inc. pays a 1.16% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Tempus AI for 23 Days on average.
| RMD | TEM | |
|---|---|---|
Market Cap | $31.89B | $12.58B |
Volume | 618,314 | 7,444,569 |
Sector | Health | Broad Market / Factor |
52-Week High | $277.88 | $99.28 |
52-Week Low | $182.82 | $41.55 |
Typical Hold Time | 51 Days | 23 Days |
Enterprise Value | $31.24B | $13.21B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Tempus AI (TEM) trades at $70.93, up 0.91% today, with a bullish technical signal and strong analyst support. The stock shows robust revenue growth, with 2026 revenue reaching $1.4B, but remains unprofitable with a net margin of -17.77%. Recent FDA clearance for its ECG-MR AI product and positive ESMO Congress abstracts highlight innovation momentum, though negative cash flow from operations and insider selling pose concerns.
Outlook is cautiously optimistic given 64% buy ratings and a $72.60 consensus target, but profitability challenges and high valuation multiples (P/S 8.61, P/B 28.27) demand scrutiny. Key risks include sustained losses, competitive pressures, and reliance on financing activities for liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
